---
figid: PMC6060673__fped-06-00199-g0001
figlink: /pmc/articles/PMC6060673/figure/F1/
number: F1
caption: 'Immunomodulatory approaches for the treatment and prevention of neonatal
  sepsis. (A) PTX, a phosphodiesterase inhibitor, mediates most of its functions by
  enhanced cyclic AMP (cAMP) due to a reduced degradation of cAMP (, ). Relatively
  high concentrations of adenosine are present in neonatal blood plasma and neonatal
  mononuclear cells demonstrate increased sensitivity to the cAMP-mediated inhibitory
  effects of adenosine (, ). As immunomodulatory properties of PTX are mediated via
  adenosine-dependent pathways, adenosine and PTX in combination, lead to a profound
  inhibitory effect on pro-inflammatory cytokine production (). On neonatal APCs,
  PTX demonstrates anti-inflammatory properties by (1) down-regulating TLR4 expression
  and signaling, (2) downregulation of surface molecules such as CD14 and CD11b, and
  (3) inhibition of inflammatory cytokine production (). (B) The microbiome of premature
  infants has a smaller proportion of beneficial bacteria and higher numbers of pathogenic
  bacteria compared to term infants, likely owing to higher frequencies of cesarean
  sections, antibiotic use, exposure to the hospital environment, and artificial feeding
  (). The administration of probiotics up-regulates local and systemic immunity by
  (1) decreasing proinflammatory cytokines, (2) increasing the production of anti-inflammatory
  cytokines, and (3) decreasing the permeability of the gut to bacteria and toxins
  (). (C) Human milk contains a range of distinct bioactive molecules that protect
  against infection and inflammation including immunoglobulins, long-chain PUFAs,
  and LF. Among them, the antimicrobial and immunomodulatory effects of lactoferrin
  are best studied: (1) Inhibition of bacterial adhesion and biofilm formation (–),
  (2) binding of endotoxins from intestinal pathogens (), (3) blocking of receptors
  essential for epithelial invasion of microbes () thereby (4) prevention of bacterial
  translocation (), (5) promotion of anergic/anti-inflammatory effects in LPS or LTA
  stimulated macrophages by TLR expression and pathway interference (, ).'
pmcid: PMC6060673
papertitle: 'Immunomodulation to Prevent or Treat Neonatal Sepsis: Past, Present,
  and Future.'
reftext: Simone S. Schüller, et al. Front Pediatr. 2018;6:199.
pmc_ranked_result_index: '231745'
pathway_score: 0.8008094
filename: fped-06-00199-g0001.jpg
figtitle: Immunomodulatory approaches for the treatment and prevention of neonatal
  sepsis
year: '2018'
organisms:
- Homo sapiens
ndex: ed7c974e-de95-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6060673__fped-06-00199-g0001.html
  '@type': Dataset
  description: 'Immunomodulatory approaches for the treatment and prevention of neonatal
    sepsis. (A) PTX, a phosphodiesterase inhibitor, mediates most of its functions
    by enhanced cyclic AMP (cAMP) due to a reduced degradation of cAMP (, ). Relatively
    high concentrations of adenosine are present in neonatal blood plasma and neonatal
    mononuclear cells demonstrate increased sensitivity to the cAMP-mediated inhibitory
    effects of adenosine (, ). As immunomodulatory properties of PTX are mediated
    via adenosine-dependent pathways, adenosine and PTX in combination, lead to a
    profound inhibitory effect on pro-inflammatory cytokine production (). On neonatal
    APCs, PTX demonstrates anti-inflammatory properties by (1) down-regulating TLR4
    expression and signaling, (2) downregulation of surface molecules such as CD14
    and CD11b, and (3) inhibition of inflammatory cytokine production (). (B) The
    microbiome of premature infants has a smaller proportion of beneficial bacteria
    and higher numbers of pathogenic bacteria compared to term infants, likely owing
    to higher frequencies of cesarean sections, antibiotic use, exposure to the hospital
    environment, and artificial feeding (). The administration of probiotics up-regulates
    local and systemic immunity by (1) decreasing proinflammatory cytokines, (2) increasing
    the production of anti-inflammatory cytokines, and (3) decreasing the permeability
    of the gut to bacteria and toxins (). (C) Human milk contains a range of distinct
    bioactive molecules that protect against infection and inflammation including
    immunoglobulins, long-chain PUFAs, and LF. Among them, the antimicrobial and immunomodulatory
    effects of lactoferrin are best studied: (1) Inhibition of bacterial adhesion
    and biofilm formation (–), (2) binding of endotoxins from intestinal pathogens
    (), (3) blocking of receptors essential for epithelial invasion of microbes ()
    thereby (4) prevention of bacterial translocation (), (5) promotion of anergic/anti-inflammatory
    effects in LPS or LTA stimulated macrophages by TLR expression and pathway interference
    (, ).'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - NFKB1
  - LY96
  - IL1B
  - RELA
  - IL6
  - MFAP1
  - NFKB2
  - CSF2RA
  - ITGAM
  - IRF6
  - F3
  - CXCL8
  - IL10
  - CD14
  - TGFB3
  - TH
  - REL
  - TNF
  - RELB
  - TGFB1
  - CD79A
  - TLR4
  - TGFB2
  - Pentoxifylline
  - Adenosine
  - Lactoferrin
  - O
  - AMP
  - LPS
genes:
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: MD2
  symbol: MD-2
  source: hgnc_alias_symbol
  hgnc_symbol: LY96
  entrez: '23643'
- word: IL-1B
  symbol: IL-1B
  source: hgnc_alias_symbol
  hgnc_symbol: IL1B
  entrez: '3553'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELA
  entrez: '5970'
- word: IL-6.*
  symbol: IL6
  source: hgnc_symbol
  hgnc_symbol: IL6
  entrez: '3569'
- word: AMP
  symbol: AMP
  source: hgnc_alias_symbol
  hgnc_symbol: MFAP1
  entrez: '4236'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB2
  entrez: '4791'
- word: CD116
  symbol: CD116
  source: hgnc_alias_symbol
  hgnc_symbol: CSF2RA
  entrez: '1438'
- word: CD11b
  symbol: CD11b
  source: hgnc_alias_symbol
  hgnc_symbol: ITGAM
  entrez: '3684'
- word: LPS
  symbol: LPS
  source: hgnc_prev_symbol
  hgnc_symbol: IRF6
  entrez: '3664'
- word: CD14(2
  symbol: CD142
  source: hgnc_alias_symbol
  hgnc_symbol: F3
  entrez: '2152'
- word: CXCL-8
  symbol: CXCL8
  source: hgnc_symbol
  hgnc_symbol: CXCL8
  entrez: '3576'
- word: IL-1B-
  symbol: IL1B
  source: hgnc_symbol
  hgnc_symbol: IL1B
  entrez: '3553'
- word: IL-10
  symbol: IL-10
  source: hgnc_alias_symbol
  hgnc_symbol: IL10
  entrez: '3586'
- word: CD14
  symbol: CD14
  source: hgnc_symbol
  hgnc_symbol: CD14
  entrez: '929'
- word: TGFB
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB3
  entrez: '7043'
- word: Th,helpercell
  symbol: TH
  source: hgnc_symbol
  hgnc_symbol: TH
  entrez: '7054'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: REL
  entrez: '5966'
- word: TNFA
  symbol: TNF-alpha
  source: hgnc_alias_symbol
  hgnc_symbol: TNF
  entrez: '7124'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELB
  entrez: '5971'
- word: TGFB
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB1
  entrez: '7040'
- word: IgA
  symbol: IGA
  source: hgnc_prev_symbol
  hgnc_symbol: CD79A
  entrez: '973'
- word: TLR4
  symbol: TLR4
  source: hgnc_symbol
  hgnc_symbol: TLR4
  entrez: '7099'
- word: TGFB
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB2
  entrez: '7042'
chemicals:
- word: Pentoxifylline
  source: MESH
  identifier: D010431
- word: Adenosine
  source: MESH
  identifier: D000241
- word: Lactoferrin
  source: MESH
  identifier: C432397
- word: O
  source: MESH
  identifier: D013481
- word: AMP
  source: MESH
  identifier: D000249
diseases:
- word: LPS
  source: MESH
  identifier: C536528
figid_alias: PMC6060673__F1
redirect_from: /figures/PMC6060673__F1
figtype: Figure
---
